| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Benzyl L-leucyl-L-phenylalaninate TFA is not a drug and does not have a direct biological target. It is a synthetic intermediate used in the preparation of longer peptide chains and certain pharmaceutical compounds. Its primary role is to serve as a C-terminal building block in solid- or solution-phase peptide synthesis, where the benzyl ester acts as a protecting group for the carboxylic acid of phenylalanine.
|
|---|---|
| ln Vitro |
As a chemical intermediate, this compound is not designed to have inherent in vitro biological activity. Its purpose is as a building block for larger molecules. The biological activity of any peptide synthesized using this intermediate would be determined by the sequence of the final peptide. For instance, this specific dipeptide is a fragment of the proteasome inhibitor Carfilzomib, which has potent anti-cancer activity, but the intermediate itself is inactive.
|
| ln Vivo |
This compound is not an active pharmaceutical ingredient and does not have in vivo biological activity on its own. It is used exclusively as a reagent for chemical synthesis. As a protected dipeptide, it is likely to be rapidly hydrolyzed by esterases and peptidases in vivo if administered systemically, breaking it down into its constituent amino acids, which are non-toxic and are used for normal protein synthesis. It would not be administered in animal studies as a therapeutic agent.
|
| Enzyme Assay |
For non-cell-based assays, this compound is used as a reactant in peptide coupling. A standard protocol for its use as a peptide intermediate involves deprotecting the benzyl ester group by catalytic hydrogenation (H2, Pd/C in methanol) to reveal the free carboxylic acid for further coupling. Alternatively, the TFA salt can be neutralized with a base like DIPEA (diisopropylethylamine) in DCM to free the amine for coupling with another protected amino acid.
|
| Cell Assay |
This chemical intermediate is not used directly in cell-based assays. To use it in a biological context, the compound must first be deprotected and extended into a longer bioactive peptide. For example, to make Carfilzomib, this dipeptide would be coupled with a specific epoxyketone warhead. The final product, after purification, would then be dissolved in DMSO and added to cancer cells. The intermediate itself is not added directly to cells.
|
| Animal Protocol |
This compound is not used in animal experiments. It serves as a synthetic starting material. For pharmacokinetic studies of a final peptide drug, the radiolabeled version of the drug would be synthesized. This could be achieved by starting with a tritiated or 13C/15N-labeled version of this intermediate. The final labeled drug would then be administered to rodents, and samples would be analyzed by LC-MS/MS to determine its PK profile.
|
| ADME/Pharmacokinetics |
As a protected dipeptide (MW 482.49), Benzyl L-leucyl-L-phenylalaninate TFA is lipophilic and would be expected to have good cell membrane permeability due to the benzyl group. However, its TFA salt form improves its solid-state stability. Pharmacokinetic studies are not performed on this synthetic intermediate. If it were to enter the bloodstream, the benzyl ester would be rapidly cleaved by plasma esterases, and the TFA salt would be dissociated.
|
| Toxicity/Toxicokinetics |
Formal toxicology data is not available for this compound as it is a chemical reagent, not a clinical drug. It is intended for research use only and not for human use. It should be handled with caution using appropriate personal protective equipment (lab coat, gloves, safety glasses). As a TFA salt, it may be irritating to the skin, eyes, and respiratory tract. It is not a known carcinogen or reproductive hazard.
|
| Additional Infomation |
Benzyl L-leucyl-L-phenylalaninate TFA is a key synthetic intermediate for the anticancer drug Carfilzomib (Kyprolis®). Carfilzomib is an irreversible proteasome inhibitor used to treat multiple myeloma. This dipeptide fragment provides the P2 (leucine) and P1 (phenylalanine) residues of the drug. The benzyl ester serves as a temporary protecting group for the carboxylic acid during the assembly of the larger molecule. This compound exemplifies how non-bioactive intermediates are used in the manufacturing of complex pharmaceutical drugs.
|
| Molecular Formula |
C24H29F3N2O5
|
|---|---|
| Molecular Weight |
482.49267745018
|
| Exact Mass |
482.202
|
| CAS # |
70637-28-4
|
| PubChem CID |
118704860
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
34
|
| Complexity |
538
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
FC(C(=O)O)(F)F.O=C(C(CC(C)C)N)NC(C(=O)OCC1C=CC=CC=1)CC1C=CC=CC=1
|
| InChi Key |
RIZSOQODQYBBID-FKLPMGAJSA-N
|
| InChi Code |
InChI=1S/C22H28N2O3.C2HF3O2/c1-16(2)13-19(23)21(25)24-20(14-17-9-5-3-6-10-17)22(26)27-15-18-11-7-4-8-12-18;3-2(4,5)1(6)7/h3-12,16,19-20H,13-15,23H2,1-2H3,(H,24,25);(H,6,7)/t19-,20-;/m0./s1
|
| Chemical Name |
benzyl (2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-phenylpropanoate;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~51.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 25 mg/mL (51.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 250.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0726 mL | 10.3629 mL | 20.7258 mL | |
| 5 mM | 0.4145 mL | 2.0726 mL | 4.1452 mL | |
| 10 mM | 0.2073 mL | 1.0363 mL | 2.0726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
